Abzena in $300-Million Deal for ADC Linker TechnologyBy
Abzena, a Cambridge, UK-headquartered services and technology provider for biopharmaceuticals, has signed a licensing agreement with an unnamed San Diego-based biopharmaceutical company for ThioBridge, Abzena’s proprietary antibody drug conjugate (ADC) linker technology.
The agreement has the potential to reach over $300 million, comprising license fees and milestone payments to Abzena. In addition, Abzena would also receive royalties on sales of approved products that incorporate the ThioBridge technology developed by its undisclosed partner.
ThioBridge is a technology platform that links antibodies and other proteins to drugs while maintaining the stability of the antibody and a consistent drug-to-antibody ratio, providing a homogeneous product. The agreement covers the use of ThioBridge in up to 10 ADCs across a wide range of indications. Abzena has also entered a master services agreement, which enables multiple programs of work to be undertaken over an extended period, relating to the company’s chemistry services.